Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian F Chapin

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Cancer|January 19, 2017
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry dataStephen B Williams, Jinhai Huo, Karim Chamie, et al.
Radiology. Imaging Cancer|February 25, 2022
<sup>18</sup>F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-AnalysisDivya Yadav, Hyunsoo Hwang, Wei Qiao, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|October 21, 2025
The intersection of race and adiposity in prostate cancer: a narrative reviewMatthew Smith, Tarek Lawen, Rebekka S Garcia, et al.
Radiology|January 25, 2022
Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRIWeranja K B Ranasinghe, Patricia Troncoso, Devaki Shilpa Surasi, et al.
Prostate Cancer and Prostatic Diseases|September 17, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancerAndrew M Fang, Brian F Chapin, Charles W Shi, et al.
Prostate Cancer and Prostatic Diseases|July 11, 2018
Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative researchMuammer Altok, Bumyang Kim, Bina B Patel, et al.
BJU International|January 18, 2019
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?Chad A Reichard, Yaw A Nyame, Debasish Sundi, et al.
Practical Radiation Oncology|April 17, 2020
Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare DataChad Tang, Xiudong Lei, Grace L Smith, et al.
Prostate Cancer and Prostatic Diseases|October 11, 2025
Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancerXiaolei Shi, Jarey H Wang, Brian F Chapin, et al.
Cancer|March 15, 2021
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomyLamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Cancer|January 19, 2017
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry dataStephen B Williams, Jinhai Huo, Karim Chamie, et al.
Radiology. Imaging Cancer|February 25, 2022
<sup>18</sup>F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-AnalysisDivya Yadav, Hyunsoo Hwang, Wei Qiao, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|October 21, 2025
The intersection of race and adiposity in prostate cancer: a narrative reviewMatthew Smith, Tarek Lawen, Rebekka S Garcia, et al.
Radiology|January 25, 2022
Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRIWeranja K B Ranasinghe, Patricia Troncoso, Devaki Shilpa Surasi, et al.
Prostate Cancer and Prostatic Diseases|September 17, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancerAndrew M Fang, Brian F Chapin, Charles W Shi, et al.
Prostate Cancer and Prostatic Diseases|July 11, 2018
Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative researchMuammer Altok, Bumyang Kim, Bina B Patel, et al.
BJU International|January 18, 2019
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?Chad A Reichard, Yaw A Nyame, Debasish Sundi, et al.
Practical Radiation Oncology|April 17, 2020
Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare DataChad Tang, Xiudong Lei, Grace L Smith, et al.
Prostate Cancer and Prostatic Diseases|October 11, 2025
Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancerXiaolei Shi, Jarey H Wang, Brian F Chapin, et al.
Cancer|March 15, 2021
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomyLamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, et al.
Pageof 12